Pemazyre

Active substance pemigatinib
Holder Incyte Corporation
Status closed
Indication adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy
Public documents Approbation

Information for the patient

Informed consent

Last update  11/08/2022

 

Last updated on 13/02/2024